FDA Approves First Broad RAS Inhibitor for Pancreatic Cancer on World Pancreatic Cancer Day

Targeted therapies and early detection initiatives are reshaping outcomes for patients facing metastatic pancreatic adenocarcinoma, marking a significant scientific turning point on World Pancreatic Cancer Day.

New Therapies Block RAS Proteins to Improve Survival

  • Targeting the Driver: New therapies are specifically designed to block RAS proteins, which act as the primary cancer-driving pathway in the vast majority of pancreatic malignancies.
  • Survival Improvements: Recent clinical trial data demonstrate marked improvements in median overall survival rates when compared directly against traditional chemotherapy regimens.
  • Supportive Care Integration: Combining active oncological treatment with early interdisciplinary palliative care helps patients maintain functional status and adherence to therapy protocols.

FDA Approval of Daraxonrasib

In August, the Food and Drug Administration approved RASONQUE (daraxonrasib) as the first broad RAS-targeted treatment for metastatic pancreatic adenocarcinoma, Oncodaily reported. Adenocarcinoma represents the most common form of pancreatic cancer, characterized by tumor spread beyond the pancreas itself.

Daraxonrasib specifically inhibits the RAS protein, which functions as the major cancer-driving pathway in the disease. In findings from the RASolute 302 clinical trial, median overall survival reached 13.2 months with daraxonrasib compared to 6.7 months with standard chemotherapy, according to SurvivorNet.

This breakthrough addresses a disease that has historically remained extremely difficult to treat. U.S. Representative Terri Sewell convened lawmakers, researchers, advocates, industry experts, and a pancreatic cancer survivor on Capitol Hill for a roundtable discussion marking World Pancreatic Cancer Day, highlighting these advances alongside the enactment of the Nancy Gardner Sewell MCED Act, the House reported.

Among the participants at the roundtable were Pancreatic Cancer Action Network (PanCAN) President and CEO Julie Fleshman, Harvard Medical School and Dana-Farber Cancer Institute expert Brian Wolpin, Revolution Medicines Senior Director of Payer and Health Systems Liaison Don Frost, and pancreatic cancer survivor Joe Damore.

Maintaining Functional Status Determines Clinical Trial Eligibility

Maintaining functional status is critical not only for quality of life but also for determining patient eligibility for emerging therapies.

The RASolute 302 clinical trial specifically enrolled patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, a standard clinical scale used by physicians to measure a patient’s ability to carry out daily living activities. Patients experiencing severe symptoms during first-line therapy often risk losing eligibility for subsequent lines of treatment or clinical trials.

FDA Approves First Broad RAS Inhibitor for Pancreatic Cancer on World Pancreatic Cancer Day
Photo: SurvivorNet
Treatment Arm Median Overall Survival Patient Population Criteria
Daraxonrasib (RASolute 302 Trial) 13.2 months Metastatic pancreatic adenocarcinoma; ECOG 0 or 1
Standard Chemotherapy (RASolute 302 Trial) 6.7 months Metastatic pancreatic adenocarcinoma; ECOG 0 or 1

“Pancreatic cancer is a really difficult diagnosis. Patients are not only worried about their prognosis, but they’re also often having a lot of symptoms from the cancer itself, including jaundice,” Dr. Goodman told SurvivorNet.

Jaundice manifests as a yellowing of the skin and eyes occurring when a tumor physically blocks the bile duct. Additional clinical symptoms frequently include a lack of appetite, significant weight loss, and localized abdominal or back pain.

Supportive Oncology and Nutritional Care

To help patients manage both the disease manifestations and the physiological stress of treatment initiation, medical teams are increasingly integrating supportive care early in the disease course.

As part of its 2024 updates, the American Society of Clinical Oncology advises oncology practitioners to pair ongoing cancer therapies with referrals to dedicated interdisciplinary palliative care teams for individuals diagnosed with advanced solid tumors. Nutritional support also serves as a critical treatment enabler, ensuring patients maintain sufficient caloric intake despite systemic symptoms.

FDA Approves First Broad RAS Inhibitor for Pancreatic Cancer on World Pancreatic Cancer Day
Photo: House

“Oftentimes it’s a multi-step process for the treatment. So it’s also really important to include a nutritionist because so much of what we do … really is dependent on the patient being healthy enough to get their therapy,” Dr. Goodman told SurvivorNet.

“And if they’re losing weight, that can be a real problem. So we are making sure they’re eating the right things, getting the right number of calories.”

Patients Need Performance Evaluation Before Targeted Therapy

Patients with advanced pancreatic cancer must be evaluated carefully for functional performance status before initiating targeted therapies like daraxonrasib. Individuals presenting with unmanaged obstructive jaundice, severe treatment-related toxicities, or poor performance status outside trial inclusion parameters (such as an ECOG score above 1) may require stabilization or palliative interventions before proceeding with novel RAS inhibitors.

Federal Funding and Future Research Directions

Federal investments continue to sustain momentum against the disease. Earlier in the year, Representative Sewell successfully led efforts to restore and increase appropriations for pancreatic cancer research through the Congressionally Directed Medical Research Program (CDMRP) within the federal defense bill after funding was entirely eliminated in the previous fiscal year under a continuing resolution, according to U.S. Congresswoman Terri Sewell.

Sewell secured a historic $20 million allocation for the program, representing a $5 million increase from prior funding levels.

“From the FDA’s approval of a promising new targeted treatment to the enactment of our Nancy Gardner Sewell MCED Act, we are making meaningful progress in the fight against cancer. But we cannot afford to let up now,” said Terri Sewell, U.S. Representative.

As research collaborations expand between academic medical centers, federal agencies, and pharmaceutical developers, the integration of targeted RAS inhibition and early detection multi-cancer early detection (MCED) frameworks offers a renewed clinical outlook for patients diagnosed with advanced pancreatic malignancies.

The Pancreatic Cancer Action Network (PanCAN) was founded in February 1999 by a group of survivors and caregivers and held its first advocacy event, “Inaugural One Voice Against Cancer,” in Washington, D.C., the following year. By 2002, the organization had established 40 volunteer affiliates across the United States and later opened a Government Affairs & Advocacy office in the capital in 2006.

PanCAN initiated the Know Your Tumor precision medicine service in 2014 and launched the Clinical Trial Finder online resource in 2015. The organization has awarded 174 grants to 170 scientists at 64 institutions since 2003, with a cumulative projected research investment of approximately $104 million; grantees leveraged early funding into $311 million in subsequent research support.

References

  • SurvivorNet: Keeping Pancreatic Cancer Patients Fit for Therapy and Supportive Care Guidelines

Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.

Photo of author

Health Desk

Health Desk at Archyde.

Players Debate If Blizzard Can Police Auction House RMT Gold Transfers